TriVascular Technologies, which develops new stent grafts for endovascular aortic repair (EVAR), announced terms for its IPO on Thursday. The Santa Rosa, CA-based company plans to raise $91 million by offering 6.5 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $284 million.
TriVascular Technologies, which was founded in 1998 and booked $20 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol TRIV. It initially filed confidentially on December 16, 2013. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.
